UCB Canada supports efforts to identify personalized treatment approach for drug-resistant epilepsy


» Share this page


Tuesday December 10, 2013

UCB Canada supports efforts to identify personalized treatment approach for drug-resistant epilepsy

Genome Canada and Génome Québec are pleased to announce UCB Canada Inc.’s contribution to a four-year study aimed at developing a personalized medicine approach to the early diagnosis of various types of epilepsy.



The $10.8 million project, “Personalized medicine in the treatment of epilepsy”, forms the Canadian Epilepsy Network (CENet) and is led by Dr. Patrick Cossette at the University of Montreal Hospital Research Centre* (CRCHUM), as well as co-leaders, Dr. Jacques Michaud, Sainte-Justine University Hospital Research Center in Montreal, and Dr. Berge Minassian, The Hospital for Sick Children in Toronto.


Download the document (PDF format)




Back to news list